New Personalized mRNA Vaccine Keeps Pancreatic Cancer At Bay 6 Years After Treatment

New Personalized mRNA Vaccine Keeps Pancreatic Cancer At Bay 6 Years After Treatment

The treatment staved off cancer for seven of eight patients with a condition where the odds are rarely that good.

New Pancreatic Cancer Vaccine Gave Patients 6 Years

Two breakthrough treatments, including an mRNA vaccine that kept patients alive for six years and a drug that shrank tumors in nearly half of pancreatic cancer patients, are giving hope to pancreatic cancer patients.

Autogene Cevumeran & The Future of Personalized Cancer Vaccines

Data from a phase 1 trial suggest that durable, vaccine-induced T-cell memory may be achievable even in pancreatic ductal adenocarcinoma.

🧬 From 13% to 88%: This many survive pancreatic cancer thanks to new vaccine

Seven of eight patients who responded to the personalized mRNA vaccine for pancreatic cancer are still alive six years after treatment.The vaccine is tailored to each patient using genetic material from their unique tumor cells.A Phase 2 study with more participants is already underway.How the vaccine worksPancreatic cancer is one of the deadliest cancers. Fewer than 13 percent of those diagnosed survive more than five years. New data from a Pha…

Trials for a pancreatic cancer mRNA vaccine: “Nearly 90% of ...

Trials for a pancreatic cancer mRNA vaccine: “Nearly 90% of people whose immune systems responded to the vaccine were still alive up to six years after receiving the last treatment. The five-year survival rate for pancreatic cancer is around 13%…”